Tetrathiomolybdate

DB05088InvestigationalSmall molecule

Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of... It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.

Mechanism: Tetrathiomolybdate has demonstrated the ability to inhibit fibrosis in a number of well established animal models through the sequestration of available copper and inhibition of key fibrotric cytokines, including secreted protein acid rich in cysteine (SPARC), NFkappaB, TGF-beta, FGF-2, IL-1, IL-6, IL-8, and connective tissue growth factor (CTGF).
Curator reviewed
Primary indication: Investigated for use/treatment in liver disease and pulmonary fibrosis.Curator reviewed
Formula / weight: MoS₄ · 224.19 g/mol (avg)
Also known as: Thiomolybdate · Tiomolibdate ion
Code names: ATN-224

Resolves to

Compound

UNII91U3TGV99TCAS16330-92-0ChEBI30703PubChem25199766

Structure

InChIKeyCXVCSRUYMINUSF-UHFFFAOYSA-NSMILES[S-][Mo]([S-])(=S)=S

Targets

P00441SOD1P05067APP

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

40Drug interactionsStructured to mechanism, not free text

24Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tetrathiomolybdate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account